Background: Over the last few decades, new synthetic insulin analogues have been developed. Their measure ment is of prime importance in the investigation of hypoglycaemia, but their quantification is hampered by variable crossreactivity with many insulin assays. For clinical analysis, it has now become essential to know the potential crossreactivity of analogues of interest. Methods: In this work, we performed an extensive study of insulin analogue crossreactivity using numerous human insulin immunoassays. We investigated the cross reactivity of five analogues (lispro, aspart, glulisine, glar gine, detemir) and two glargine metabolites (M1 and M2) with 16 commercial human insulin immunoassays as a function of concentration.
Introduction
Measurement of insulin concentration is useful to inves tigate hypoglycaemia, βcell function, insulin resistance, insulinoma, and to determine the pathogenesis of type 1 and 2 diabetes. Even if, owing to analytical pitfalls [1, 2] , commercially available human insulin assays are still awaiting standardisation, they are currently used in clini cal investigation [2] [3] [4] [5] . Insulin is synthesised in the βcells of the islets of Langerhans as a proinsulin precursor, which is processed to form insulin and Cpeptide. Both are secreted in equimolar amounts into the portal circulation. Thus, recombinant insulin administration can be sus pected when insulin and Cpeptide levels are discordant: a suppressed or undetectable Cpeptide value associated with a normaltoelevated insulin value is in favour of syn thetic insulin administration taking into account their dis tinct halflife. When pharmaceutical recombinant insulin, with a sequence identical to that of human insulin, is administered, human insulin assays are usually coupled with Cpeptide measurements to distinguish exogenous synthetic insulin injections from physiological insulin.
Owing to the limiting pharmacokinetic and pharma codynamic features of the recombinant human insulin sequence, rapid and/or longacting analogues have been used since 1996 [6] . These new synthetic insulin analogues have complicated the detection of synthetic insulin. Thevis et al. have largely described mass spectrometrybased methods for insulin analogue assessment [7] [8] [9] [10] [11] . However, these methods are highly technically demanding. They have been described for antidoping test purposes and are not widespread. Furthermore, as preliminary immuno extraction is required prior to chromatographic and mass spectrometric analysis, assay performances are limited to detection without quantification.
Human insulin immunoassays are easy to perform, but clinicians and clinical chemists must be aware that possible crossreactivity has already been highlighted between endogenous or exogenous standard insulin and analogues in sera assays [12] [13] [14] . Failing that, misdiagno sis can occur as described in the observation by Krull et al. [15] . In that case, hypoglycaemia was initially associated to nonmeasurable plasma insulin levels (Elecsys, Roche Diagnostics), which could be attributed to deficiencies in counterregulatory hormones such as cortisol or growth hormone, severe hepatic or renal failure or large nonislet tumours producing IGF2. However, a second insulin assay performed with Advia Centaur ® (Siemens), yielded high "insulin" levels due to significant crossreactivity with insulin glargine and lispro. A secret insulin administra tion, responsible for the factitious hypoglycaemia, was thus detected [15] . In another case report, despite a serum insulin concentration within the reference range, hypo glycaemia was observed. The surreptitious association of human insulin with glargine and insulin aspart escaped detection owing to low crossreactivity between the ana logues and human insulin in the insulin assays [16] . Lack of control of crossreactivity of insulin analogues leads to misdiagnosis with clearly established clinical impact. As a consequence, different studies focused on the determina tion of the crossreactivity of various analogues using one particular insulin assay [14, [17] [18] [19] [20] [21] [22] . Those works showed, for example, that the Architect insulin assay (Abbott Labo ratories) had a low crossreactivity to the insulin analogue aspart, whereas it detected lispro and glargine, in con centrations as high as the theoretical concentrations [12] . More recently, Vieira et al. (2007) showed crossreactivity between insulin glargine and regular human insulin in an immunofluorimetric assay provided by PerkinElmer [14] . However, from a practical point of view, it is essential to define the technique (or combination of techniques) that will highlight the presence or absence of insulin ana logues. This involves extending such studies to a wide range of immunoassays, an undertaking initiated by Owen in 2004 [13] .
To address this situation, in the present study, we set about an extensive evaluation of the crossreactivity of rapid (lispro, glulisine, aspart) and longacting (detemir, glargine and its two metabolites: M1, M2) analogues with numerous and frequently used commercial assays. A comparison of 16 human insulin immunoassays has been performed for both insulin analogues and glargine metabolites. This study includes glulisine, the latest addi tion to rapid analogues, whose crossreactivity has not been studied at all, and the glargine metabolites whose crossreactivity has only been assessed with very few assays [14, 15] . Four insulin analogue concentrations were analysed ranging from 10 to 200 mU/L in PBS1% BSA (or 60-1200 pmol/L for glargine metabolites) to determine their crossreactivity with human insulin as a function of concentration.
Materials and methods

Insulin, insulin analogues and metabolites
The structure and activity of insulin analogues are presented in the Supplemental Data Table S1 , which accompanies the article at http://www.degruyter.com/view/j/cclm.2014.52.issue3/issuefiles/ cclm.2014.52.issue3.xml. Human recombinant insulin (Actrapid 100 IU/mL), aspart (Novorapid 100 U/mL) and detemir (Levemir 100 U/mL) were obtained from Novo Nordisk (Puteaux, France), lispro (Humalog 100 U/mL) from Lilly (Suresnes, France), glargine (Lantus 100 U/mL) and glulisine (Apidra 100 U/mL) from SanofiAventis (Paris, France). M1 and M2 (glargine metabolites) were kind gifts from SanofiAventis (Professor J. Sandow, Frankfurt, Germany).
Insulin assays
The characteristics of the commercially available insulin assays are described in the Supplemental Data, Table S2 
Samples
Insulin analogues contained in pen treatment units, and glargine metabolites were successively diluted in PBS1% BSA to final concen trations of 10, 30, 100, and 200 mU/L, and 60, 180, 600 and 1200 pmol/L, respectively, using a semiautomated diluter (Microlab 500, Hamilton, Reno, USA). The dilution steps of the stock solutions were validated by using a 125 Ilabelled solution. Each dilution point was prepared three times.
In order to study the influence of insulin analogues and glar gine metabolites on human insulin measurement they were mixed at a final concentration of 100 mU/L and 600 pmol/L, respectively, with recombinant insulin (final concentration of 100 mIU/L) in PBS 1% BSA (data not shown).
Matrix
As glargin is metabolised by enzymes such as carboxypeptidases present in serum or plasma, the former were replaced by protein supplemented PBS for the assays. We consequently tested differ ent BSA concentrations ranging from 1% to 8% in PBS, in absence of insulin with 17 assays (data not shown). The Immulite assay was initially part of the study, but the results were not included in our paper, because the matrix alone (PBSBSA without analogue or insu lin) surprisingly displayed results between 19 mIU/L and 41 mIU/L for BSA concentrations between 1% and 8%. That matrix was clearly not suitable to study Immulite. We did not observe such inconsistencies with the other assays whatever the BSA concentration and PBSBSA 1% has been retained.
Statistics
In order to test the validity of the different assays, linearity tests were performed according to the method previously described [23] . When significant, the test on departure from linearity leads to the rejection of the linearity assumption. A pvalue less than 0.05 was considered as significant and indicated lack of linearity throughout the range of different concentrations. Computations were run with R 2.14″. Table 1 represents the crossreactivity values obtained, for analogues and metabolites, as a function of the molecules assessed and their concentrations, with 16 immunoassays. The percentage of crossreactivity was calculated from the ratio of the measured and nominal concentrations. The details of the methods used by the assays (type, principle, category, antibodies…) are described in the Supplemental Data, Table S2 . These assays cover the most frequently used assays in the field and the various methods: auto mated or manual as well as twosite immunometric or competition assays. As a prerequisite, we show that most commercial insulin assays (10/16) quantitatively detected human recombinant insulin (Actrapid ® ) whatever the concentrations between 10 and 200 mIU/L (Supplemen tal Data, Table S3 ). The source of discrepancies in results among commercial methods of insulin immunoassays is likely multifactorial and not explainable by a single analytical performance characteristic [4] . Matrix effects in combination with the fact that insulin assays are still calling for standardisation can explain this result [4, 24] .
Results
Insulin analogues
We studied three shortacting and two longacting insulin analogues using the same 16 commercial assays (Table 1 and Supplemental Data, Table S1 ). The crossreactivity values were comprised between 0% and 264% as a func tion of the analogues. A similar scale was also observed for a single analogue, i.e., detemir, yielding crossreactivity values between 0% and 264% as a function of the assays used. Furthermore, let us note that four assays (Elecsys Roche, Diasorin Liaison, InsIRMA Beckman and Wallac AutoDELFIA PerkinElmer) showed a high specificity to human insulin, with no or little crossreactivity whatever the analogue studied.
Glargine metabolites
Insulin glargine is a longacting human insulin analogue. Following subcutaneous administration insulin glargine precipitates. Proteolytic degradation results in two main active metabolites: M1 and M2, formed by the sequential removal of the two arginines from the carboxyterminus of the Bchain and additional deamination of threonine in position B30 [25, 26] . Their similarity with the human insulin structure led to check their crossreactivity. As with analogues, the performance of the various commer cial assays was not uniform with respect to crossreactivity with both glargine metabolites. Crossreactivity was close to 100% in five immunoassays, and at least two others displayed crossreactivity values < 5%. In general, a given assay yielded similar crossreactivity values for the two metabolites, except for Elecsys, which presented cross reactivity for M1 around 22% but none for M2. Figure S1 ). Crossreactivity was linear in 58% of the immunoassays (65/112), and some immuno assays yielded predominantly linear results whatever the analogue, i.e., InsEASIA, DIAsource and InsulinCT, Cis Bio. The linearity could not be correlated with the insulin analogue or the immunoassay methods used. Analogue concentration appears to be an important parameter to take into account in the choice of the insulin assay to be used. In some cases, statistical analysis of the results obtained with some analogues was not possible when those were under the method detection threshold (italic font in Table 1 ) (26/112). However, despite of the lack of statistical analysis, one can conclude that these methods are not suitable for the detection of these analogues.
Influence of concentration
Discussion
The aim of the current study was to highlight and measure with commonly used immunoassays the possible cross reactivity of various analogues. All the measurements were performed in the presence of albumin to limit the adsorption of analogues to plasticware occurring in the absence of protein, thus diminishing the amount avail able for detection by the assays [27] . In our work, the study of the analogues showed that four assays were specific to human insulin, resulting in negligible crossreactivity with the analogues while yield ing values > 90% for human insulin. Crossreactivity is a function of the binding of the antibodies employed in the assay. Human insulin has antigenic determinants differing (Tosoh)  10   106  122   63   16   58   60  43   63  30   109  124   67   20   60   180  50   70  100   113  126   78   36   72   600  74   84  200   112  121   79   50   76   1200  84   98 Absence of statistical analysis owing to values under the detection threshold of the method: italic font type.
( Table 1 Continued) from the antigenic sites of insulin analogues. One of them is comprised between the positions 27-30 of the Bchain [28] and the other concerns the residues 8-10 of the Achain [29, 30] . Considering the structure of the studied analogues (Supplemental Data, Table S1 ), the results suggest that at least these four assays are based on the use of antibod ies recognising the Cterminal part of the Bchain, which is altered within the sequence of the analogues studied, hence the lack of or very low crossreactivity. These results confirm and extend the scope of the lack of crossreactivity reported in 2001 using the Elecsys method applied to lispro measurements [21] . In the same way, the difference in crossreactivity between the glargine metabolites (M1 and M2) using the Elecsys assay can be explained by the struc ture of M1, with a conserved Bchain maintaining recogni tion by antibodies directed against the Cterminal part of the Bchain and probably used in the Elecsys method. M2 is not recognised owing to the alteration of the Cterminal part of the Bchain. It is of prime importance to discrimi nate glargine from its metabolites. Indeed, we henceforth know that after injection, glargine is minimally detectable in blood due to its rapid conversion into M1 and M2 metabo lites. A relation between glargine administration and a risk of cancer was assumed partly due to in vitro studies but this relation is challenged [31] . PierreEugène et al. showed that promitogenic properties of glargine in cultured cells should be abrogated in vivo by its rapid conversion into metabolites [32] . Recent studies on type 1 and 2 diabetic subjects showed that the longacting metabolic effects are related to the main metabolite M1 [33, 34] reinforcing the importance of its specific detection and quantification.
The effect of the primary ligand (human insulin in our study) on the degree of observed crossreactivity has been previously described. According to Miller and Valdes, depending on the assay, human insulin may moderately decrease or increase crossreactivity with insulin ana logues [35, 36] . In our work, the simultaneous presence of the primary ligand (human insulin) and of the crossreac tant have miscellaneous effects depending on the assay and on the analogue assessed (data not shown).
The various immunoassays used were either twosite specific immunometric or competitive assays (Supplemen tal Data, Table S2 ). We can note in Table 1 that competitive assays (CoatACount, Siemens; Human Insulin Specific RIA, Millipore; INSIK5, DiaSorin; InsulinCT, Cis Bio) were able to detect all the analogues and metabolites resulting in nonnegligible crossreactivity. As a consequence, these four methods do not appear in the last column of Table  2 , which highlights methods without crossreactivity with any analogue or metabolite. This result is consist ent with the fact that the polyclonal antibodies used for competitive assays provide lesser specificity compared to monoclonal antibodies.
In competitive immunoassays using polyclonal anti bodies (e.g., Human insulin specific RIA and INSIK5), the decrease in measured crossreactivity as the concentration of crossreactant increases has already been described by Miller and Valdes [35, 36] . In a polyclonal antiserum, mul tiple antibodies display varying affinities for the primary antigen.
Sets of antibodies with low affinity for the standard antigen may have a high affinity for the crossreactant. The first small amounts of crossreactant easily displace bound label from these less specific antibodies. As the crossreactant saturates the less specific antibodies, addi tional amounts of crossreactant are less likely to displace bound label from the more specific antibodies. Owen et al. had previously studied the crossreactivity of three recom binant insulin analogues (insulin aspart, glargine, insulin lispro) with five commercial insulin immunoassays in the presence of BSA. The large variability in the degree of cross reactivity of those analogues with the five different commer cial assays is noteworthy [13] . We have reached the same conclusion, i.e., that of a large variability in crossreactivity through the extensive study of five insulin analogues and two metabolites using 16 immunoassays. Table 2 summa rises the specific assay(s) that can be used ( > 90% cross reactivity) as well as the commercial assays without any crossreactivity ( < 5%) for each analogue. It shows that few methods allow the detection of glulisine, but for one with crossreactivity around 90% (InsulinCT, CisBio). For every other analogue, there is at least one available assay able to detect the molecule with high crossreactivity (90%-110%). As a consequence, when secret insulin administration is suspected one of the four human insulinspecific assays should be used in parallel with a second insulin assay presenting significant crossreactivity with insulin ana logues. Krull et al. [15] have shown the benefit of knowing the capacity of individual assays to measure or not insulin analogues. In their work, they evidenced a case of facti tious hypoglycaemia by selfadministration of lispro and glargine, thanks to the complementary use of both Elecsys ® and Advia Centaur ® assays and their discordant results [15] . This work shows that insulin immunoassays have various degrees of crossreactivity with insulin analogues and their metabolites. However, knowing that kit manu facturers may change lots of reagent antibodies (mainly for polyclonal antibodies) [37] sometimes without commu nicating such changes to laboratory users, we therefore do recommend the use of specific inhouse quality controls (i.e., samples with analogue dilutions) to validate new kit lots before assessing insulin analogues. Nevertheless, this study brings a very useful comparison of immunoas says available to clinicians when they must discriminate between insulin of various origins.
